gastric ulcers

CJ-42794 (CJ-042794) is a selective antagonist of the prostaglandin E receptor subtype 4 (EP4), inhibiting [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5. It exhibits a binding affinity that is at least 200-fold more selective for the human EP4 receptor than for other human EP receptor subtypes (EP1, EP2, and EP3) (IC50: 8.5 (pKi)).

Abeprazan hydrochloride (Fexuprazan hydrochloride) is an effective reversible potassium-competitive acid blocker with oral activity, inhibiting H+, K+ -atPase by competitive binding to potassium ions without acid activation. Abeprazan hydrochloride is a proton pump inhibitor (PPI) that acts by reducing gastric acid production and is used to treat gastric acid-related disorders, such as gastroesophageal reflux disease (GERD) and peptic ulcers.

Bermoprofen (AD-1590) is an orally active non-steroidal anti-inflammatory compound with analgesic properties, utilized in gastric ulcer studies.

Thioflosulide (L-745337) is a selective and potent COX2 inhibitor with an IC50 of 2.3 nM, exhibiting anti-inflammatory activity for the study of gastric ulcers.

ICI 162,846 is an orally active and potent H2 receptor antagonist that inhibits gastric secretion and may be used in the study of duodenal ulcers.

Rioprostil is a methyl prostaglandin E1 analog that decreases gastric acid secretion and enhances the gastric mucus-bicarbonate barrier. It is effective in the treatment of gastric ulcers and gives significant protection against NSAID-induced gastric muco

NC-1300-B inhibits H(+)-K(+)-ATPase and is used in the study of gastric ulcers.

Mifentidine (DA 4577) is an orally available H2 receptor antagonist for the study of gastric emptying and experimental gastric and duodenal ulcers.

Lansoprazole (A-65006) is a 2, 2, 2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)

Proglumide (Binoside) is a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. Proglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.

Ranitidine (HSDB 3925) is a non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.

Thiazolidinone-Derivatives-1 inhibits the secretion of gastric acid and can be used in research on the treatment of gastric and duodenal ulcers.

Gefarnate is a synthetic compound used for the treatment of gastric ulcers,and also used in the treatment of dry eye syndrome.

Methyl retinoate (Retinoic acid, methyl ester) induces aseptic inflammation at the site of administration in in vivo experiments, which causes an increase in the number of leukocytes in the blood and a decrease in the levels of red blood cells and Hb.Methyl retinoate promotes spontaneous leukemia.Methyl retinoate can be Used in the treatment of gastric hypertrophy and ulcers due to vitamin A deficiency. Translated with www.DeepL.com Translator (free version)

Levocarnitine propionate (L-Propionylcarnitine) is a propionyl-coenzyme A (Pro-CoA) derivative with anti-ischemic effects and high affinity for muscle L-carnitine transferase. Levocarnitine propionate enhances substrate oxidation and mitochondrial respiration in the heart of diabetic rats, reduces gastric ulcer area, induces mucosal recovery, and can be used to study acute respiratory distress syndrome and chronic gastric ulcers in Alzheimer's disease.

Misoprostol acid, an active metabolite of Misoprostol, is used for treating non-steroidal anti-inflammatory drug-induced (NSAID) gastric ulcers.

Rabeprazole sodium (Habeprazole Sodium) is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.

Ilaprazole sodium (IY-81149 sodium) , a substituted benzimidazole prodrug, is a selective and irreversible proton pump inhibitor. A weak base, Ilaprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+ K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.

Ilaprazole (IY-81149) is a proton pump inhibitor used in the treatment of dyspepsia gastroesophageal reflux disease (GORD GERD) and duodenal ulcer. Studies also showed that Ilaprazole significantly prevented the development of reflux oesophagitis.

Rabeprazole (LY307640) is an H+ K+-ATPase inhibitor that inhibits cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis and can be used in the study of gastric ulcers.

Oxyphenonium Free Base, a quaternary ammonium anticholinergic agent, exhibits peripheral side effects paralleling those of ATROPINE. It functions as an adjunct in managing gastric and duodenal ulcers and alleviates visceral spasms. The compound is also employed as eye drops to induce a mydriatic effect.

JAK05 exhibits inhibitory activity against Helicobacter pylori, effectively suppressing strains J63, J196, and J107, with a MIC of 3-5 µg mL. It shows affinity for binding to H+ K+-ATPase, COX-1 2, TNF-α, and PGE2, and possesses antioxidant and anti-inflammatory properties. In a rat model of ethanol-induced gastric ulcers, JAK05 demonstrates anti-ulcer activity.

Urease-IN-19 (Compound 3c) is a potent inhibitor of urease, demonstrating an IC50 value of 2.7 µM. It shows potential for use in research related to kidney stones and gastric ulcers.

Enprostil is a synthetic PGE2 analog that has an inhibitory effect on gastric acid secretion, a mucoprotective effect, and a postprandial lowering effect on gastrin. It has efficient and safe in the therapy of gastroduodenal ulcers.